Focused On-demand Library for Chitinase-3-like protein 1

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

We use our state-of-the-art dedicated workflow for designing focused libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.

Several key aspects differentiate our library:

Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

P36222

UPID:

CH3L1_HUMAN

Alternative names:

39 kDa synovial protein; Cartilage glycoprotein 39; YKL-40

Alternative UPACC:

P36222; B2R7B0; P30923; Q8IVA4; Q96HI7

Background:

Chitinase-3-like protein 1, known by alternative names such as 39 kDa synovial protein, Cartilage glycoprotein 39, and YKL-40, plays a pivotal role in the body's response to environmental changes. This carbohydrate-binding lectin, while lacking chitinase activity, is instrumental in tissue remodeling, inflammatory responses, and facilitating bacterial invasion into colonic mucosa.

Therapeutic significance:

The protein's involvement in diseases like Asthma-related traits 7 and Schizophrenia highlights its potential as a target for therapeutic intervention. Understanding the role of Chitinase-3-like protein 1 could open doors to potential therapeutic strategies, especially in managing inflammatory and psychotic disorders.